2021, Number 2
<< Back Next >>
CorSalud 2021; 13 (2)
Relevance of aspirin (acetylsalicylic acid) in the prevention of cardiovascular events
Díaz-Rodríguez YL
Language: Spanish
References: 5
Page: 256-259
PDF size: 142.45 Kb.
Text Extraction
No abstract.
REFERENCES
Gaziano JM, Brotons C, Coppolecchia R, CricelliC, Darius H, Gorelick PB, et al. Use of aspirin toreduce risk of initial vascular events in patients atmoderate risk of cardiovascular disease (ARRIVE):a randomised, double-blind, placebo-controlledtrial. Lancet. 2018;392(10152):1036-46. [DOI]
Mahmoud AN, Gad MM, Elgendy AY, Elgendy IY,Bavry AA. Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized controlled trials. Eur Heart J. 2019;40(7):607-17. [DOI]
Castilla-Guerra L, Fernández-Moreno MDC, de laVega-Sánchez JM, León Jiménez D. Evaluacióndel riesgo hemorrágico de la terapia antitrombótica en pacientes con ictus. Clin Investig Arterioscler. 2019;31(6):282-8. [DOI]
Steering Committee of the Physicians' HealthStudy Research Group. Final report on the aspirincomponent of the ongoing Physicians' HealthStudy. N Engl J Med. 1989;321(3):129-35. [DOI]
Hennekens CH, Dalen JE. Aspirin in the treatmentand prevention of cardiovascular disease: pastand current perspectives and future directions.Am J Med. 2013;126(5):373-8. [DOI]
Full text